<DOC>
	<DOCNO>NCT01766739</DOCNO>
	<brief_summary>The purpose study test safety GL-ONC1 vaccinia virus different dose level . The investigator want find effect , good and/or bad , patient malignant pleural effusion . A malignant pleural effusion build fluid chest cavity cause cancer .</brief_summary>
	<brief_title>Intra-pleural Administration GL-ONC1 , Genetically Modified Vaccinia Virus , Patients With Malignant Pleural Effusion : Primary , Metastases Mesothelioma</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Pleural Effusion , Malignant</mesh_term>
	<criteria>Diagnosis histologically cytologically document , malignant pleural effusion ( primary nonsmallcell lung carcinoma , mesothelioma , histology ) , free pleural space ( partial total ) permit intrapleural drug instillation . This include cytologically negative pleural effusion conjunction histologically proven malignancy involve pleura . Age must ≥ 18 year . All acute toxic effect prior radiotherapy , chemotherapy , surgical procedure must resolve Common Terminology Criteria Adverse Events ( CTCAE , Version 4.0 ) Grade ≤ 1 . Any surgery , general anesthesia administer , must occur least 14 day prior study enrollment . Chemotherapy , radiotherapy immunotherapy must stop 7 day prior receive study drug ; however , small field palliative radiotherapy , TKI therapies hormonal therapy allow . Patients stage IV malignancy ( nonmesothelioma ) must brain scan ( MRI CT contrast ) show evidence disease progression within 8 week study enrollment . ECOG Zubrod ≤ 2 . Required baseline laboratory data include : Absolute neutrophil count ( ANC ) ≥ 1.5 × 109 [ SI unit 10^9/L ] , Platelets ≥ 100 ×10^9 [ SI unit 10^9/L ] , Hemoglobin ≥ 9.0 g/dL [ SI unit gm/L ] , Serum creatinine ≤ 1.5 × upper limit normal ( ULN ) , Bilirubin ≤ 1.5 × ULN , AST/ALT ≤ 2.5 × ULN ( ≤ 5 × ULN presence liver metastasis ) Negative pregnancy test female childbearing potential . Pregnant breastfeed woman . Patients fever active systemic infection , include know HIV , hepatitis B C. Patients immunosuppressive therapy immune system disorder , include autoimmune disease . Concurrent steroid use equivalent 20 mg/day prednisone ( equivalent ) . Prior splenectomy . Previous organ transplant . Patients clinically significant dermatological disorder , e.g. , eczema psoriasis , judge principal investigator , unhealed skin wound ulcer . Clinically significant cardiac disease ( New York Heart Association , Class III IV ) . Dementia alter mental status would prohibit informed consent . Other severe , acute , chronic medical psychiatric condition laboratory abnormality , may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment principal investigator , would make patient inappropriate study . Known allergy ovalbumin egg product . Prior gene therapy treatment prior therapy cytolytic virus type . Concurrent therapy investigational anticancer agent . Concurrent antiviral agent active vaccinia virus ( e.g . cidofovir , vaccinia immunoglobulin ) study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>GL-ONC1</keyword>
	<keyword>pleural effusion</keyword>
	<keyword>12-169</keyword>
</DOC>